Introduction {#Sec1}
============

Acromegaly, usually caused by a somatotroph pituitary adenoma, is an endocrine disorder with an estimated prevalence of 125 cases per million \[[@CR1]\]*.* Due to the slowly progressive nature of the disease, it often takes 6.6--10.2 years until acromegaly is diagnosed \[[@CR2]\]. Clinical presentation of acromegaly reflects chronic GH excess and comprises a broad spectrum of comorbidities, such as cardiovascular features (i.e. hypertension), metabolic features (i.e. diabetes mellitus), respiratory features (i.e. sleep apnea), bone and joint features, soft tissue and skin changes, malignancies, endocrine consequences (thyroid goiter) and a variety of neurological complications, such as nerve compression syndromes \[[@CR3]\]. Unless adequate biochemical control is achieved, acromegaly is associated to elevated morbidity and mortality, mostly because of cardiovascular disease \[[@CR4], [@CR5]\].

Therapy for acromegaly represents a demanding task for the physician, since a subset of patients exhibit treatment-resistant disease. Management options include transsphenoidal surgery, representing the first-line treatment for acromegaly*,* radiation and medical therapy. Treatment with somatostatin analogues inhibits GH secretion and induces tumour shrinkage, whereas the GH receptor antagonist pegvisomant effectively blocks GH action in the periphery leading to disease control \[[@CR6]\]. Effective control of GH and IGF-1 excess improves comorbidities as well as lowers mortality rates \[[@CR7]\].

It is known that GH and IGF-1 play an important role in the regulation of metabolism and body composition \[[@CR8]\]. GH exhibits lipolytic effects and can cause insulin resistance, whereas IGF-1 exhibits anti-lipolytic and insulin-sensitising effects.

In acromegaly, an alteration of the body composition, including an increase in body water and lean body mass and a reduction in body fat, occurs.

Under therapy, and after the achievement of biochemical control, a reduction in body water and fat-free mass, and an increase in body fat have been reported \[[@CR9], [@CR10]\]. However, it is not clear if this increase results in higher adiposity measurements compared to a respective control group.

Few studies have examined anthropometric and cardiovascular risk parameters in patients with acromegaly under therapy. Recently, Freda et al. reported a lower visceral and subcutaneous fat mass in a cross-sectional study with 24 adults with active acromegaly compared to healthy controls. Sucunza et al. \[[@CR8], [@CR11]\] concluded from their cross-sectional study in 60 acromegalic patients that control of acromegaly reverts decreased fat mass. Regarding cardiovascular risk parameters, a more atherogenic lipoprotein profile in active acromegalic patients, consisting of higher levels of triglycerides and apolipoprotein B, was reported in the study of Boero et al. \[[@CR12]\]. In another study, patients with active acromegaly presented with a higher insulin resistance index and fibrinogen levels than patients and subjects in control groups; CRP, leucocyte count, factor VIII and NT-pro BNP were similar in the three groups \[[@CR13]\].

The aim of our study was to evaluate the cardiovascular risk profile of "biochemically cured" acromegalic patients by comparing their anthropometric parameters (height, weight, body mass index (BMI), waist and hip circumference, waist to height ratio), and cardiovascular risk biomarkers, to an age- and gender-matched primary care control group. Since acromegaly is associated with an increased risk of diabetes mellitus, which might influence the calculations, we performed stratified analyses in diabetic and non-diabetic patients separately.

Subjects and methods {#Sec2}
====================

Participants {#Sec3}
------------

Eighty-one patients with previously diagnosed acromegaly were recruited at the Endocrine Outpatient Unit of the Max Planck Institute of Psychiatry (MPIP) and the Department of Internal Medicine, Ludwig-Maximilians-University (LMU) in Munich. We sampled 320 age- and gender-matched control subjects in a fasting state (ratio 1:4) from the DETECT-cohort (Diabetes cardiovascular risk evaluation; targets and essential data for commitment and treatment, <http://www.detect-studie.de/>), a nationally representative cohort of patients attending a primary care practice in Germany \[[@CR14], [@CR15]\]. A 2 acromegalic patients had only two adequate DETECT-matches, so that the control group comprised of 320 instead of 324 subjects. The control groups for the subgroup analyses, as well as the diabetic control group, were recruited from the same DETECT-cohort (*n* = 320). All subjects gave their written informed consent. The study was approved by the local ethical committee.

Diabetes cardiovascular risk-evaluation: targets and essential data for commitment of treatment is a large, multistage, cross-sectional study of 55,518 unselected consecutive patients in 3,188 nationally representative primary care offices in Germany with a laboratory and follow-up component in a random subset of 7,519 patients. For all patients, a comprehensive standardised clinical evaluation (patients' self-report and physicians' assessments) was conducted. Patients in the prospective subset were additionally characterised by an extensive standardised laboratory programme. The main target of the DETECT study was the assessment of cardiovascular risk.

Assessment of comorbidities, biochemical variables and covariates {#Sec4}
-----------------------------------------------------------------

Clinical characteristics of the subjects were collected with regard to disease history, tumour characteristics, previous and current therapy, and comorbidities as well as current complaints. Comorbidities were diagnosed based on the physicians' assessments according to respective guidelines.

In the case of missing data or uncertainty, additional information was obtained by file review. Biochemical control in acromegalic patients was defined as (a) GH below 1 μg/L during a glucose tolerance test over 2 h, or (b) age- and gender-adjusted normal values for IGF-1 within two standard deviations \[[@CR16]\].

Regarding measurement of biochemical variables, serum concentrations of GH were measured using the automated Advantage chemiluminescent assay system (Nichols Diagnostics Institute, Bad Vilbel, Germany), and IGF-1 was determined on the continuous random access analyzer Immulite^®^ 2000 IGF-1 (Fa. DPC). Fasting plasma glucose and HbA1c were determined using the GLU and HBA1C II system of Roche, respectively. Cholesterol and triglycerides were also determined on a Roche analyser (CHOL, TG). Lipoproteins HDL and LDL were determined using the Roche HDL-C plus 3rd generation and LDL-C plus 2nd generation assay, respectively. Lipoprotein (a) was determined by nephelometry.

Within the DETECT-study, blood samples were collected and shipped by courier at room temperature within 24 h to the central laboratory (Medical University of Graz, Austria). Upon arrival, the samples were centrifuged immediately and serum and plasma were stored at 20°C until further processing. Clinical chemical parameters, as well as cholesterol and triglycerides, were determined on a Roche Modular automatic analyzer. Lipoproteins were determined electrophoretically on the HEENA SAS-3/SAS-4 system. HbA1c was determined chromatographically on an ADAMS HA 8160 analysing system.

Statistical analysis {#Sec5}
--------------------

The statistical analysis was performed using the software package STATA 10.0 (Stata Corp). Statistical tests were conducted by logistic regression models for categorical variables and linear regression models for dimensional variables. Standard errors were estimated by Taylor linearization to account for the dependent clustered data structure.

Results {#Sec6}
=======

Demographic and clinical characteristics of the acromegalic study group {#Sec7}
-----------------------------------------------------------------------

The acromegalic group (*n* = 81) comprised of 43 female (53.1%) and 38 male patients (46.9%) with a mean age of 54.7 ± 1.4 years. Patients with acromegaly had a high prevalence of pituitary macroadenomas (65%). 73 patients (90.1%) received transsphenoidal surgery as the primary therapy; the mean time after surgery was 10.15 ± 0.88 years. 44 patients (54.3%) received medical treatment including 10 patients (12.3%) currently under dopamine agonists, 28 patients currently under somatostatin analogs and 9 patients (11.1%) currently under pegvisomant. A 20 patients (24.7%) were irradiated, 10 patients (12.3%) received Gammaknife, 1 patient (1.2%) Cyberknife and 5 patients (6.2%) stereotactic fractionated radiatio. The mean time after radiotherapy was 9.1 ± 1.61 years. The acromegalic patients often suffered from arthralgia (65.4%), pituitary deficiency (59.3%), arterial hypertension (54.3%), carpal tunnel syndrome (45.7%), sleep apnea (34.6%), diabetes mellitus (27.2%) and malignancies (11.1%).

Acromegaly was biochemically controlled in 49 patients (58%) at the time of study. The mean actual GH and IGF-I SE scores were 2.8 ± 0.59 and 214.2 ± 18.0 μg/L, respectively.

Comparisons of anthropometric parameters and cardiovascular risk biomarkers between all acromegalic patients and primary care controls {#Sec8}
--------------------------------------------------------------------------------------------------------------------------------------

Table [1](#Tab1){ref-type="table"} summarises the results on anthropometric parameters and laboratory findings. The whole group of 81 acromegalic patients presented with significantly higher anthropometric parameters, such as weight, BMI, waist and hip circumference, in comparison to their respective controls (86.6 ± 17.8 *vs.* 79.8 ± 17.4 kg; *P* = 0.002; 29.2 ± 5.2 *vs.* 27.5 ± 5.6 kg/m^2^; *P* = 0.014; 100.0 ± 14.3 *vs.* 95.7 ± 15.5 cm; *P* = 0.026; 110.6 ± 9.2 *vs.* 105.6 ± 12.0 cm; *P* = 0.001, respectively).Table 1Comparisons of comorbidities, anthropometric parameters and cardiovascular risk biomarkers between patients with acromegaly (*n* = 81) and the age- and gender-matched DETECT-controls (*n* = 320)Patients with acromegaly (*n* = 81)DETECT-control group (*n* = 320)*P*-value*n*%*n*%Comorbidities Hypertension4454.312137.8**0.008** Diabetes mellitus2227.25818.10.073 Coronary heart disease78.6309.40.840 Myocardial infarction11.21136.7**0.001** Cerebral insult44.900.0-- Malignancies911.1103.1**0.005** Pituitary deficiency4859.3 Corticotrope deficiency3543.2 Thyreotrope deficiency2227.2 Gonadotrope deficiency3340.7 Growth hormone deficiency33.7Mean (SD)Mean (SD)*P*-valueAnthropometric parameters Height (cm)172.4 (12.0)170.1 (9.3)0.107 Weight (kg)86.6 (17.8)79.8 (17.4)**0.002** BMI (kg/m^2^)29.2 (5.2)27.5 (5.6)**0.014** Waist circumference (cm)100.0 (14.3)95.7 (15.5)**0.026** Hip circumference (cm)110.6 (9.2)105.6 (12.0)**0.001** Waist to height ratio0.58 (0.09)0.56 (0.09)0.174Biochemical parameters IGF-1 (μg/L)214.2 (161.2)131.5 (54.3)**0.000**Cardiovascular risk biomarkers Fasting plasma glucose (mg/dL)93.5 (16.5)104.1 (35.1)**0.001** HbA1c (%)5.7 (0.5)5.6 (1.0)0.550 Total cholesterol (mg/dL)215.8 (39.5)226.6 (44.0)**0.045** Triglycerides (mg/dL)121.1 (63.6)160.8 (155.3)**0.001** HDL (mg/dL)60.4 (21.4)53.0 (17.6)**0.009** LDL (mg/dL)139.4 (37.4)131.0 (32.4)0.093 Lipoprotein (a) (mg/dL)36.1 (43.5)33.3 (47.3)0.707*Note*: Significant effects are bold typed

Additionally, cardiovascular risk biomarkers, such as fasting plasma glucose, total cholesterol, triglycerides and HDL levels, were more favourable in the acromegalic group compared to the age- and gender-matched controls.

Regarding comorbidities, acromegalic patients suffered significantly more often from hypertension (54.3 *vs.* 37.8%; *P* = 0.008) and malignancies (11.1 *vs.* 3.1%; *P* = 0.005), but less often from myocardial infarction (1.2 *vs.* 36.7%; *P* = 0.001), compared to their respective controls. In detail, the malignancies reported included two patients with skin cancer, one patient with colorectal carcinoma, one patient with renal carcinoma, one patient with thyroid carcinoma, one patient with cervical carcinoma, one patient with breast cancer, one patient with both breast and skin cancer and one patient with an unknown malignancy.

Comparisons of anthropometric parameters and cardiovascular risk biomarkers between biochemically cured and uncontrolled patients and respective non-acromegalic controls {#Sec9}
-------------------------------------------------------------------------------------------------------------------------------------------------------------------------

We went onto stratify the study group into controlled and uncontrolled patients and compared them to their respective primary care control patients.

When evaluating biochemically controlled acromegalic patients in comparison to their respective DETECT controls, anthropometric measurements such as weight (85.6 ± 17.9 *vs.* 78.5 ± 18.5 kg; *P* = 0.015), BMI (29.5 ± 5.9 *vs.* 27.3 ± 5.8 kg/m^2^; *P* = 0.020), waist (100.9 ± 16.8 *vs.* 94.8 ± 15.5 cm; *P* = 0.031) and hip circumference (110.7 ± 9.9 *vs.* 105.0 ± 11.7 cm; *P* = 0.001) were significantly higher in biochemically controlled patients. Cardiovascular risk biomarkers, such as fasting plasma glucose (90.9 ± 16.7 *vs.* 104.8 ± 39.3 mg/dL; *P* = 0.000) and triglycerides (118.5 ± 59.4 *vs.* 153.8 ± 123.1 mg/dL; *P* = 0.006), were significantly lower in biochemically controlled patients. Since radiation might also play a role in causing pituitary deficiency with effects on both body composition and cardiovascular risk biomarkers, we also performed the same analyses excluding patients who had been irradiated or were pituitary-deficient. We observed similar results with significant differences in BMI, waist and hip circumference between the groups (*P* = 0.039, 0.015 and 0.001, respectively).

No significant differences in anthropometric parameters remained between uncontrolled acromegalic patients and their controls after stratification, indicating that the observed differences between the acromegalic and the control group can be fully attributed to the controlled acromegalic patient group (Table [2](#Tab2){ref-type="table"}).Table 2Comparisons of comorbidities, anthropometric parameters and cardiovascular risk biomarkers between biochemically controlled (*n* = 49) and uncontrolled patients (*n* = 31) and the age- and gender-matched DETECT-controls (*n* = 196 and *n* = 120, respectively)Patients with uncontrolled acromegaly (*n* = 31)Patients with controlled acromegaly (*n* = 49)*P*-value controlled versus uncontrolled acromegalyDETECT-control group, patients with uncontrolled acromegaly (*n* = 120)*P*-value versus uncontrolled acromegalyDETECT-control group, patients with controlled acromegaly (*n* = 196)*P*-value versus controlled acromegaly*n*%*n*%*n*%*n*%Comorbidities Hypertension1651.62755.10.7624638.30.1917538.30.037 Diabetes mellitus722.61530.60.4382319.20.6763517.9**0.049** Coronary heart disease412.936.10.309119.20.544199.70.443 Myocardial infarction00.012.0--436.4--736.8**0.001** Cerebral insult00.048.2--00.0--00.0-- Malignancies516.148.20.28354.2**0.029**52.60.080Mean (SD)Mean (SD)Mean (SD)Mean (SD)Anthropometric parameters Height (cm)174.5 (13.5)170.7 (10.6)0.188170.9 (9.9)0.165169.3 (8.7)0.391 Weight (kg)87.1 (17.2)85.6 (17.9)0.70781.4 (15.4)0.10178.5 (18.5)**0.015** BMI (kg/m^2^)28.5 (4.0)29.5 (5.9)0.37627.9 (5.2)0.52327.3 (5.8)**0.020** Waist circumference (cm)98.2 (9.8)100.9 (16.8)0.38497.0 (15.6)0.60694.8 (15.5)**0.031** Hip circumference (cm)109.9 (7.4)110.7 (9.9)0.719106.5 (12.6)0.063105.0 (11.7)**0.001** Waist to height ratio0.56 (0.06)0.59 (0.10)0.1900.57 (0.09)0.7120.56 (0.09)0.089Biochemical parameters IGF-1 (μg/L)317.1 (216.7)149.1 (47.7)**0.000**135.5 (52.5)**0.000**128.7 (55.5)**0.011**Cardiovascular risk biomarkers Fasting plasma glucose (mg/dL)97.5 (15.9)90.9 (16.7)0.084103.7 (27.3)0.107104.8 (39.3)**0.000** HbA1c (%)5.8 (0.5)5.6 (0.4)0.1045.6 (0.9)0.0695.7 (1.1)0.566 Total cholesterol (mg/dL)204.6 (42.1)223.6 (36.8)0.058225.0 (38.3)**0.022**227.7 (47.6)0.534 Triglycerides (mg/dL)118.2 (62.3)118.5 (59.4)0.987174.4 (198.5)**0.011**153.8 (123.1)**0.006** HDL (mg/dL)62.2 (24.8)60.0 (19.2)0.70251.2 (17.5)**0.040**54.1 (17.6)0.077 LDL (mg/dL)128.8 (40.1)146.9 (34.2)0.070129.6 (28.5)0.929131.9 (34.8)**0.013** Lipoprotein (a) (mg/dL)40.3 (48.6)34.1 (41.7)0.70632.3 (43.4)0.58534.0 (49.9)0.985*Note*: Significant effects are bold typed

In order to exclude type 2 diabetes mellitus as a potential influence on our calculations, we performed further stratified analyses with acromegalic patients and primary care controls, with and without the diagnosis of type 2 diabetes mellitus.

Comparisons of patients with acromegaly with and without diabetes mellitus and the respective primary care controls {#Sec10}
-------------------------------------------------------------------------------------------------------------------

Twenty-two acromegalic subjects were diagnosed with diabetes mellitus (age- and gender-matched control group of patients with diabetes mellitus *n* = 88) during the course of the disease or treatment; 12 patients with acromegaly and diabetes mellitus had been treated with dopamine agonists, 12 with the somatostatin analogue octreotide, 5 with lanreotide and 4 with the GH receptor antagonist pegvisomant (more than one therapy modality possible).

As presented in Table [3](#Tab3){ref-type="table"}, we did not see significant differences in anthropometric parameters between acromegalic patients with diabetes mellitus and controls with diabetes mellitus. Additionally, the acromegalic patient group with diabetes mellitus even displayed an improved cardiovascular risk profile regarding HDL (61.7 ± 20.8 *vs.* 53.3 ± 16.5 mg/dL; *P* = 0.010) and lipoprotein (a) levels (13.8 ± 8.5 *vs.* 37.6 ± 54.7 mg/dL; *P* = 0.021), but not regarding total cholesterol, triglycerides and LDL. Acromegalic patients without diabetes mellitus presented significantly more often with hypertension (49.2 *vs.* 37.9%; *P* = 0.007), but with lower fasting plasma glucose (89.9 ± 11.9 *vs.* 104.3 ± 36.8 mg/dL; *P* = 0.011), total cholesterol (214.3 ± 39.0 *vs.* 227.1 ± 45.9 mg/dL; *P* = 0.031) and triglycerides levels (107.1 ± 54.4 *vs.* 158.8 ± 128.2 mg/dL; *P* = 0.000) compared to their respective controls.Table 3Comparisons of comorbidities, anthropometric parameters and cardiovascular risk biomarkers between acromegalic patients with (*n* = 22) and without diabetes mellitus (*n* = 59) and the age- and gender-matched DETECT-controls (*n* = 88 and *n* = 232, respectively)Patients with acromegaly and no diabetes mellitus + (*n* = 59)Patients with acromegaly and diabetes mellitus (*n* = 22)*P*-value no diabetes versus diabetesDETECT-control group, patients with no diabetes (*n* = 232)P-value versus no diabetesDETECT-control group, patients with diabetes (*n* = 88)*P*-value versus diabetes*n*%*n*%*n*%*n*%Comorbidities Hypertension2949.21568.20.1338837.9**0.007**3337.50.715 Diabetes mellitus--------4218.1--1618.2-- Coronary heart disease58.529.10.9302410.30.43766.80.130 Myocardial infarction11.700.0--729.2**0.002**466.7-- Cerebral insult11.7313.60.06300.0--00.0-- Malignancies610.2313.60.66273.0**0.015**33.40.227Mean (SD)Mean (SD)Mean (SD)Mean (SD)Anthropometric parameters Height (cm)174.7 (12.1)166.0 (9.1)**0.001**171.1 (9.2)**0.006**167.3 (9.0)0.060 Weight (kg)87.3 (17.7)84.6 (18.6)0.55980.5 (17.1)**0.000**77.7 (18.2)0.449 BMI (kg/m^2^)28.6 (4.8)30.7 (6.2)0.15527.5 (5.3)**0.015**27.6 (6.1)0.831 Waist circumference (cm)98.9 (10.9)102.8 (21.4)0.44996.3 (15.9)**0.003**93.8 (14.3)0.596 Hip circumference (cm)110.8 (8.7)110.2 (10.7)0.830105.6 (12.1)**0.000**105.6 (11.9)0.829 Waist to height ratio0.57 (0.06)0.61 (0.13)0.1310.56 (0.09)0.1270.56 (0.08)0.870Biochemical parameters IGF-1 (μg/L)218.6 (152.6)202.7 (185.5)0.720135.4 (56.2)**0.000**121.4 (48.0)0.057Cardiovascular risk biomarkers Fasting plasma glucose (mg/dL)89.9 (11.9)103.6 (22.8)**0.010**104.3 (36.8)**0.011**103.5 (30.2)**0.000** HbA1c (%)5.6 (0.4)5.9 (0.6)**0.038**5.6 (1.0)**0.000**5.7 (0.9)**0.000** Total cholesterol (mg/dL)214.3 (39.0)219.8 (41.7)0.616227.1 (45.9)**0.031**225.3 (38.9)0.787 Triglycerides (mg/dL)107.1 (54.4)157.3 (72.5)**0.007**158.8 (128.2)**0.000**166.2 (211.8)0.071 HDL (mg/dL)59.9 (21.8)61.7 (20.8)0.74852.9 (18.0)0.09553.3 (16.5)**0.010** LDL (mg/dL)139.7 (37.0)138.7 (39.4)0.920131.4 (33.5)0.195130.2 (29.4)0.209 Lipoprotein (a) (mg/dL)45.6 (48.8)13.8 (8.5)**0.003**31.6 (44.3)0.28237.6 (54.7)**0.021***Note*: Significant effects are bold typed

Discussion {#Sec11}
==========

This study demonstrates that biochemically cured acromegalic patients exhibit an adverse anthropometric risk profile compared to an age- and gender-matched primary care control cohort.

Various factors could explain our reported findings. One possible reason for the adverse anthropometric measurements might be a relative "overtreatment of acromegaly" resulting in subsequent symptoms of relative growth hormone deficiency. However, in our study only three biochemically cured acromegalic patients had a low IGF-1 below two standard deviations as a potential marker of relative growth hormone deficiency, which is not sufficient to fully account for the observed effect.

Other pituitary deficiencies also might explain our findings, as suggested by Schmid et al. The authors found an increased prevalence of high BMI in patients with pituitary tumours, possibly caused by partial pituitary failure \[[@CR17]\]. In our patient sample, 48 patients (59.3%) suffered from pituitary deficiencies in total, and 19 patients (23.5%) received hormonal replacement therapy with hydrocortisone. Inadequate dosages or overtreatment could have caused the adverse anthropometric profile in these patients.

Another factor could be that acromegalic patients lack physical exercise because of persisting joint complaints or arthropathy, as reported by Biermasz et al. \[[@CR18]\]. As arthralgia was reported by 65.4% of the patients in this cohort, this might have contributed greatly to the observed effect \[[@CR19]\].

Additionally, the medical treatment itself might lead to the increased measurements for body mass and body fat. Plöckinger et al. \[[@CR20]\], for instance, proposed a significant increase in intra-abdominal fat mass during therapy with the GH receptor antagonist pegvisomant, while subcutaneous fat was not significantly different. In this acromegalic cohort, the significant number of nine patients (11%) were being treated with pegvisomant at the time of study which might explain a large proportion of the observed results.

As a limitation of our study, we have to consider that the measurements reported here are restricted to anthropometric parameters without direct measurements of lean tissue mass or fat mass, since a DEXA measurement or other more site-specific measurements were not part of the DETECT study. On the other hand, anthropometric measurements alone are already strong indicators for morbidity and mortality, as published by Schneider et al. \[[@CR21]\]. We therefore believe that they should be sufficiently valid.

We can only speculate as to why some cardiovascular risk biomarkers, such as triglycerides, are more favourable than in the control group. One possible explanation could be that acromegalic patients are more aggressively treated than the control group with, i.e., a lipid lowering therapy, because of the known cardiovascular risk profile. However, we did not analyse this systematically.

Furthermore, some measurements in acromegalic patients versus DETECT subjects had to be performed with different laboratory methods, possibly yielding systematic differences and influencing our findings. However, both laboratories are part of routine standardisation procedures and should therefore deliver comparable results. Additionally, most of the examined biochemical parameters were measured with the same assays.

Moreover, cardiovascular risk biomarkers are only markers and the study was not designed to analyse "hard" end points, such as incidence of hypertension, myocardial infarction or stroke.

We also have to consider that we are comparing to a primary care patient population which is not representative for the general population, since primary care patients can be expected to be less healthy than the general population.

Nevertheless, we believe that the selection of the control group represents a valid comparison because it contrasts to a group that seeks medical advice for other reasons, reflecting a realistic scenario.

How the reported findings might influence the current management paradigm of acromegaly is not clear. However, stricter treatment goals of cardiovascular risk factors targeting mainly overweight and visceral adiposity in these patients are likely to be beneficial.
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